Historical Stock Chart
6 Months : From Jun 2019 to Dec 2019
By Cristina Roca
Sanofi SA (SAN.FR) has struck a deal to acquire exclusive over-the-counter rights for Tamiflu in the U.S., it said Tuesday.
Under the agreement struck with Roche Holding AG (RO.EB), whose subsidiary Genentech currently sells Tamiflu for prescription use in the U.S., Sanofi will be responsible for leading negotiations with the Food and Drug Administration to switch Tamiflu to over-the-counter, and will fund all studies needed to support the switch, it said.
The French pharmaceutical company will also be responsible for marketing, scientific engagement and distribution of Tamiflu over the counter in the U.S.
Tamiflu is a medicine for the prevention and treatment of influenza or flu. The deal is part of Sanofi's global cough and cold strategy, the company said.
Roche will continue to market Tamiflu in the rest of the world, Sanofi said.
No financial details of the deal were disclosed.
Write to Cristina Roca at firstname.lastname@example.org; @_cristinaroca
(END) Dow Jones Newswires
July 23, 2019 01:32 ET (05:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.